Targeting the Transforming Growth Factor-β (TGF-β) pathway to reverse the immunologically “cold” tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) remains clinically unsuccessful, warranting novel therapeutic strategies. The gene discussed is TGFB1; the disease is neoplasm.